Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   - « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Tehenes, Sandor
NCT05874401: Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan	Recruiting	4	302	Europe, RoW	Trilaciclib, G1T28, CDK 4/6 inhibitor, cyclin-dependent kinase 4/6 inhibitor, Placebo, Topotecan, Hycamtin	G1 Therapeutics, Inc.	Extensive-stage Small-cell Lung Cancer	07/27	07/27

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Tehenes, Sandor
NCT05874401: Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan	Recruiting	4	302	Europe, RoW	Trilaciclib, G1T28, CDK 4/6 inhibitor, cyclin-dependent kinase 4/6 inhibitor, Placebo, Topotecan, Hycamtin	G1 Therapeutics, Inc.	Extensive-stage Small-cell Lung Cancer	07/27	07/27